Nasdaq parade marches on as ex-Genmab crew at Y-mAbs reaps $96M

The story that Y-mAbs told for the first time in its IPO filing has earned the cancer biotech an upsized $92 million raise to power a slate of trials for its two lead drugs.

Claus Moller

Run by a group of ex-Genmab execs between New York City and Denmark, Y-mAbs traces part of its roots to Memorial Sloan Kettering, from which it licensed naxi­ta­mab and om­bur­tamab. These two drugs were key in the treatment of founder Thomas Gad’s daughter — first when she was diagnosed with high risk neu­rob­las­toma at age 2 and then when she relapsed. The 13-year-old is now disease-free.

For the public debut, Y-mAbs sold 6 million shares — up from the originally intended 5.3 million — at $16 per share. It has begun trading on Nasdaq under the symbol $YMAB.

Dan­ish ship­ping ty­coon Baron Johan Wedell-Wedells­borg owns the biggest sin­gle chunk of the stock, at 24%. Nai-Kong Che­ung, a MSK researcher credited with om­bur­tamab, held on to 8.6% of the eq­uity. That’s about what HBM got for its re­cent buy-in, and MSK owns about 10% of the com­pany.

While they have a focus on two lead drugs, CEO Claus Moller and his team also campaigned on the no­tion that they can cre­ate bet­ter bis­pe­cific an­ti­bod­ies that can kill can­cer cells faster and longer than the cur­rent gen­er­a­tion.

In one study in­volv­ing 23 chil­dren suf­fer­ing from neu­rob­las­toma, re­searchers tracked a 57% re­sponse rate with naxi­ta­mab — and the com­pany wants to pool data from an up­com­ing piv­otal study to pro­vide the ev­i­dence needed to gain an ac­cel­er­ated ap­proval — if it works in the big­ger study.

The com­pany now has a time­line for both top ther­a­pies, with BLAs slated for 2019, and plans to launch their own com­mer­cial­iza­tion ef­fort a year after that.

Prior to the IPO, the biotech had raised $120 mil­lion, with $70 mil­lion of that on tap.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->